Pharmaceutical company developing new antibiotics for drug-resistant infections alongside generic formulation manufacturing.
Pharmaceutical company developing new antibiotics for drug-resistant infections alongside generic formulation manufacturing.
Has earned mainly from selling established generic drugs in the UK, Ireland, the US and emerging markets, since it sold its Indian branded-drugs business to Dr. Reddy's in 2020. The antibiotic programme is the research bet on top of that. The Khorakiwala family, who founded the company, remain its controlling shareholders.
In one line: A small, antibiotic-focused pharma innovator.
Moat: narrow (IP / patents). One of few companies globally developing new antibiotic classes, though commercialization risk remains high.
Headquarters: Mumbai, India · Founded: 1960 · Employees: 4,084
Size Wockhardt (WOCKPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.52B, the 262nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,027 on 18 Nov 2026.
Performance Over six months the shares gained 25.1%, against +8.1% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 25.7% over the last twelve months (peer median +9.4%); the operating margin is 13.1% (peer median 12.2%).
Valuation It trades at 9.3× enterprise value to sales against a peer median of 3.2× (3rd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +54 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.4 points below its cost of capital (16.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹37.5B | ₹33.2B | ₹29.1B | ₹27.9B | ₹26.5B |
| Revenue growth | — | +14% | +5% | +5% | — |
| Gross profit | ₹14.6B | ₹9.63B | ₹6.81B | ₹5.64B | ₹4.56B |
| EBITDA | ₹7.21B | ₹5.74B | ₹3.00B | ₹1.47B | ₹790M |
| Net income | ₹4.10B | ₹2.13B | -₹470M | -₹4.63B | -₹5.59B |
| Free cash flow | n/a | ₹640M | -₹2.48B | -₹340M | ₹1.11B |
| Capital expenditure | n/a | ₹3.64B | ₹3.65B | ₹2.16B | ₹2.09B |
| Total debt | ₹22.4B | ₹22.3B | ₹20.2B | ₹23.6B | ₹21.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Wockhardt WOCKPHARMA.NS | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 6.8× | 28.7% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 3.8× | 28.4% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 2.8× | 21.1% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 2.9× | 8.8% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.5B | +5% | -4% | 9% | 3.5× | 30.7% |
| Basilea Pharmaceutica BSLN.SW | $1.04B | +33% | +5% | 24% | 3.2× | -5.6% |
| Shionogi & 4507.T | $17.6B | +3% | +46% | 29% | 4.9× | 0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | WOCKPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.3% | +2.6% | 8th highest of 21 |
| 6-month return | +25.1% | +8.1% | 7th highest of 20 |
| Distance from 52-week high | -16.3% | -23.4% | 7th highest of 21 |
| Revenue growth (TTM) | +25.7% | +9.4% | 7th highest of 18 |
| Operating margin | 13.1% | 12.2% | 8th highest of 16 |
| EV / Sales | 9.3× | 3.2× | 3rd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 58.0% | -0.4% | most demanding of 11 |
| Growth delivered (Del g) | +4.2% | +9.2% | 3rd lowest of 11 |
| Hurdle (Req g minus delivered) | +53.8 pp | -11.8 pp | most demanding of 11 |
| ROIC minus cost of capital | -11.4 pp | +4.3 pp | 4th lowest of 16 |
| EV / EBITDA | 48.3× | 14.5× | 3rd most expensive of 9 |
| Net debt / EBITDA | 2.2× | 1.4× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | 8.4× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 2.6× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 3.8× | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 2.5× | 4.7% | +4.5% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 4.2× | 1.2% | +12.1% |